186 related articles for article (PubMed ID: 38353722)
21. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
22. Adherence to adjuvant endocrine therapy among White British and ethnic minority breast cancer survivors in the United Kingdom.
McGuinness S; Hughes L; Moss-Morris R; Hunter M; Norton S; Moon Z
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13722. PubMed ID: 36255032
[TBL] [Abstract][Full Text] [Related]
23. Sociodemographic Variations in Women's Reports of Discussions With Clinicians About Breast Density.
Kressin NR; Wormwood JB; Battaglia TA; Slanetz PJ; Gunn CM
JAMA Netw Open; 2023 Nov; 6(11):e2344850. PubMed ID: 38010653
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
25. Does patient health literacy impact adherence to adjuvant endocrine therapy in breast cancer patients?
Keim-Malpass J; Doede A; Showalter SL
Patient Prefer Adherence; 2019; 13():47-51. PubMed ID: 30636869
[TBL] [Abstract][Full Text] [Related]
26. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
Chlebowski RT; Haque R; Hedlin H; Col N; Paskett E; Manson JE; Kubo JT; Johnson KC; Wactawski-Wende J; Pan K; Anderson G
Breast Cancer Res Treat; 2015 Dec; 154(3):609-16. PubMed ID: 26602222
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.
Lipkus IM; Peters E; Kimmick G; Liotcheva V; Marcom P
Med Decis Making; 2010; 30(4):464-73. PubMed ID: 20160070
[TBL] [Abstract][Full Text] [Related]
28. Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: nature and relevance for non-adherence.
Wouters H; van Geffen EC; Baas-Thijssen MC; Krol-Warmerdam EM; Stiggelbout AM; Belitser S; Bouvy ML; van Dijk L
Breast; 2013 Oct; 22(5):661-6. PubMed ID: 23770134
[TBL] [Abstract][Full Text] [Related]
29. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
30. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
31. Beliefs about medicine and illness are associated with fear of cancer recurrence in women taking adjuvant endocrine therapy for breast cancer.
Corter AL; Findlay M; Broom R; Porter D; Petrie KJ
Br J Health Psychol; 2013 Feb; 18(1):168-81. PubMed ID: 23134580
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Li L; Chang B; Jiang X; Fan X; Li Y; Li T; Wu S; Zhang J; Kariminia S; Li Q
BMC Cancer; 2018 Oct; 18(1):977. PubMed ID: 30314452
[TBL] [Abstract][Full Text] [Related]
33. Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials.
Ibrahim EM; Al-Hajeili MR; Bayer AM; Abulkhair OA; Refae AA
Med Oncol; 2017 Jul; 34(7):131. PubMed ID: 28620883
[TBL] [Abstract][Full Text] [Related]
34. Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer.
Malinowski C; Lei X; Zhao H; Giordano SH; Chavez-MacGregor M
JAMA Oncol; 2022 Jun; 8(6):863-870. PubMed ID: 35389432
[TBL] [Abstract][Full Text] [Related]
35. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
Abraham J; Caldera H; Coleman R; Elias A; Goetz MP; Kittaneh M; Lower E; Mahtani R; Terry Mamounas E; Pegram M; Rugo H; Schwartzberg L; Traina T; Vogel C
Breast Cancer Res Treat; 2018 May; 169(1):1-7. PubMed ID: 29352368
[TBL] [Abstract][Full Text] [Related]
36. Patient interactive digital support for women with adjuvant endocrine therapy in order to increase compliance and quality of life.
Bergqvist J; Lundström S; Wengström Y
Support Care Cancer; 2021 Jan; 29(1):491-497. PubMed ID: 32405965
[TBL] [Abstract][Full Text] [Related]
37. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; van den Bosch J; Maartense E; van Leeuwen-Stok AE; Liefers GJ; Nortier JWR; Rutgers EJT; van de Velde CJH;
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922787
[TBL] [Abstract][Full Text] [Related]
38. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: cochrane review.
Hind D; Wyld L; Reed MW
Br J Cancer; 2007 Apr; 96(7):1025-9. PubMed ID: 17285133
[TBL] [Abstract][Full Text] [Related]
39. Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis.
Farias AJ; Ornelas IJ; Hohl SD; Zeliadt SB; Hansen RN; Li CI; Thompson B
Support Care Cancer; 2017 Jan; 25(1):75-83. PubMed ID: 27557832
[TBL] [Abstract][Full Text] [Related]
40. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
